WINTON GROUP Ltd Acquires Shares of 26,115 IQVIA Holdings Inc. $IQV

WINTON GROUP Ltd bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 26,115 shares of the medical research company’s stock, valued at approximately $5,046,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. California State Teachers Retirement System increased its holdings in IQVIA by 18,735.4% during the second quarter. California State Teachers Retirement System now owns 49,241,537 shares of the medical research company’s stock worth $9,514,450,000 after buying an additional 48,980,106 shares during the last quarter. BlackRock Inc. bought a new position in shares of IQVIA during the 2nd quarter valued at approximately $2,811,292,000. Boston Partners bought a new position in shares of IQVIA during the 3rd quarter valued at approximately $676,698,000. Norges Bank purchased a new stake in shares of IQVIA during the 4th quarter worth approximately $497,445,000. Finally, Victory Capital Management Inc. raised its holdings in shares of IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after purchasing an additional 1,614,063 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Up 0.2%

IQVIA stock opened at $257.54 on Friday. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $271.80. The firm has a market capitalization of $42.39 billion, a price-to-earnings ratio of 31.95, a P/E/G ratio of 2.19 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a 50 day simple moving average of $235.44 and a 200 day simple moving average of $195.46.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the prior year, the business posted $2.81 earnings per share. The business’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on IQV shares. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Stifel Nicolaus upped their price target on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Mizuho increased their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, HSBC reissued a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.62.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,581 shares of company stock worth $3,796,021 in the last three months. 1.70% of the stock is currently owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.